Navigation Links
Alba Therapeutics Corporation Reports Preliminary Phase IIa,Clinical Trial Results for AT-1001 for the Treatment of Celiac,Disease

ral symptoms and outcomes improved at statistically significant levels. -- Safety and tolerability of multiple oral doses of AT-1001 in the patient population was demonstrated. There were no Severe Adverse Events and all Adverse Events were reported as mild or moderate.

"We are very encouraged by the preliminary data and look forward to applying the extensive knowledge gained in this Phase IIa exploratory clinical trial to a larger, highly powered Phase IIb gluten challenge study later this year" said Blake Paterson, M.D., Chief Executive Officer of Alba Therapeutics. Using the highly complex and ambitious seven arm study design for the Phase IIa trial, we repeated the proof of concept from the Phase Ib study, showed a statistically significant effect across a variety of measures and are well prepared to move the celiac program forward."

Based on these results, Alba will advance AT-1001 into a Phase IIb clinical study in CD subjects during the third quarter of 2007. The Phase IIb study, to be performed in multiple centers in the United States and Canada, will assess the efficacy of AT-1001 utilizing multiple endpoints, including a composite index of disease activity. The first patient is expected to be enrolled into this study in the third quarter of 2007, and the study should conclude in early 2008.

About Celiac Disease

Celiac Disease is a T-cell mediated autoimmune disease that occurs in genetically susceptible individuals and is characterized by small intestinal inflammation, injury and intolerance to gluten. According to the National Institutes of Health, CD affects approximately 3 million Americans. The only current treatment for CD is complete elimination of gluten from the diet, which results in remission for some patients.

About Alba

Alba Therapeutics Corporation is a privately held biopharmaceutical company based in Baltimore, Ma
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:9/22/2014)... NORTH CHICAGO, Ill. , Sept. 22, 2014 ... that data from several clinical studies evaluating potential ... be presented at the upcoming 2014 European Society ... in Madrid, Spain . Data ... study evaluating the safety and efficacy of veliparib ...
(Date:9/22/2014)... , Sept. 22, 2014 Arena Pharmaceuticals, Inc. (NASDAQ: ... scheduled to present a corporate overview and update at ... September 26, 2014, at 11:30 a.m. Eastern Time (8:30 ... New York City . ... available under the investor relations section of Arena,s website ...
(Date:9/22/2014)... , September 22, 2014 ... "Cell Line Development Market by Product (Equipment, Media and ... Tissue Engineering & Regenerative medicine, Toxicity Testing, Research, ... 2019", published by MarketsandMarkets, analyzes and studies the ... Browse 114 market data tables and ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4
(Date:9/22/2014)... out to be an old acquaintance: a certain module ... been considered an anchor protein. The researchers report their ... Essential: importing enzymes into peroxisome , Peroxisomes are ... fatty acids and cellular toxins. In order for them ... be imported into the peroxisomes first. The bulk is ...
(Date:9/22/2014)... of more than 30,000 nurses across Europe show that ... more likely to rate the standard of care delivered ... of their hospitals safety and omit necessary patient care. ... and the National Nursing Research Unit (NNRU) at King,s ... 450 hospitals across 12 European countries, was part of ...
(Date:9/22/2014)... Following 14 months of field ... Clearwater Clinical announced the general release of ... for smartphones. ClearSCOPE enables health professionals to capture ... and smartphone. , ENT and Urology specialists developed ... over the cost, encumbrance and slow innovation cycle ...
(Date:9/22/2014)... Thousand Oaks dentist , Dr. Sharon ... Invisalign is a type of orthodontic treatment that can ... can vary based on the extent of the dental ... needed. During this promotion, Dr. Shamoiel is offering complete ... of the adult population has an unhealthy bite, and ...
(Date:9/22/2014)... The invitation only Summit held ... 60 industry executives and thought leaders from major ... Retro Fitness, and Xsport Fitness. Also in attendance ... marketing agencies and private equity investors representing over ... , The Summit highlighted best practices for solving ...
Breaking Medicine News(10 mins):Health News:The accelerator of molecular motors 2Health News:Nurse survey shows longer working hours impact on quality of care 2Health News:ClearSCOPE 2.0 Endoscope Adaptor for Smartphones Announced; Endoscopic Video Capture Reinvented 2Health News:Thousand Oaks Cosmetic Dentist, Sharon Shamoiel DDS, Is Now Offering a Special on Invisalign 2Health News:Motionsoft Concludes Inaugural 2014 Technology Summit 2Health News:Motionsoft Concludes Inaugural 2014 Technology Summit 3
... ARBOR, Mich.---Scientists have discovered a molecular assistant called Spy that ... purposes. Bacteria are widely used to manufacture proteins used ... job. Many proteins fall apart and get cut up inside ... useless tangles instead of folding properly, as they must in ...
... FL 14 February, 2011 Elsevier / MEDai, ... announced today the launch of the latest version of ... The new version will feature an expanded set of ... new predictions: ICU Admission Prediction, Length of Stay Prediction ...
... two pesticides, rotenone and paraquat, and Parkinson,s disease. People ... times more often than non-users. The study ... National Institute of Environmental Health Sciences (NIEHS), which is ... Parkinson,s Institute and Clinical Center in Sunnyvale, Calif. ...
... 11 (HealthDay News) -- The U.S. Food and Drug ... that provides three-dimensional images of the breast for cancer ... an upgrade to Massachusetts-based Hologic Inc.,s FDA-approved two-dimensional system, ... breasts. The 3-D images may help physicians more accurately ...
... , SUNDAY, Feb. 13 (HealthDay News) -- People who ... may be protecting themselves from developing Parkinson,s disease, a ... are found in a variety of foods such as ... touted as protective against some diseases because of their ...
... News) -- Hunters who use tree stands can stay safe ... a study on tree stand safety. The reminder comes ... from tree stands and four died during the recent deer-hunting ... falls in Alabama in a single year, said the state,s ...
Cached Medicine News:Health News:Quest for designer bacteria uncovers a 'Spy' 2Health News:Elsevier/MEDai enhances real-time clinical surveillance system for hospitals 2Health News:NIH study finds 2 pesticides associated with Parkinson's disease 2Health News:FDA Approves First 3D Mammogram Device 2Health News:Berries May Offer Sweet Protection Against Parkinson's Disease 2Health News:Berries May Offer Sweet Protection Against Parkinson's Disease 3Health News:Spate of Hunter Injuries Spurs New Call for Tree Stand Safety 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: